全文获取类型
收费全文 | 98516篇 |
免费 | 6010篇 |
国内免费 | 2386篇 |
专业分类
耳鼻咽喉 | 1363篇 |
儿科学 | 1583篇 |
妇产科学 | 1197篇 |
基础医学 | 7128篇 |
口腔科学 | 2489篇 |
临床医学 | 8695篇 |
内科学 | 10282篇 |
皮肤病学 | 732篇 |
神经病学 | 5531篇 |
特种医学 | 3089篇 |
外国民族医学 | 10篇 |
外科学 | 19230篇 |
综合类 | 14939篇 |
现状与发展 | 2篇 |
一般理论 | 7篇 |
预防医学 | 7760篇 |
眼科学 | 1813篇 |
药学 | 7638篇 |
151篇 | |
中国医学 | 9017篇 |
肿瘤学 | 4256篇 |
出版年
2023年 | 1516篇 |
2022年 | 2646篇 |
2021年 | 4010篇 |
2020年 | 3488篇 |
2019年 | 5208篇 |
2018年 | 4777篇 |
2017年 | 3769篇 |
2016年 | 2766篇 |
2015年 | 2700篇 |
2014年 | 5959篇 |
2013年 | 5381篇 |
2012年 | 5176篇 |
2011年 | 6117篇 |
2010年 | 5413篇 |
2009年 | 4315篇 |
2008年 | 4058篇 |
2007年 | 4248篇 |
2006年 | 3866篇 |
2005年 | 3172篇 |
2004年 | 2648篇 |
2003年 | 2504篇 |
2002年 | 1908篇 |
2001年 | 1628篇 |
2000年 | 1380篇 |
1999年 | 1282篇 |
1998年 | 1020篇 |
1997年 | 901篇 |
1996年 | 733篇 |
1995年 | 766篇 |
1994年 | 712篇 |
1993年 | 537篇 |
1992年 | 520篇 |
1991年 | 475篇 |
1990年 | 439篇 |
1989年 | 432篇 |
1988年 | 416篇 |
1987年 | 357篇 |
1985年 | 1047篇 |
1984年 | 1019篇 |
1983年 | 776篇 |
1982年 | 882篇 |
1981年 | 842篇 |
1980年 | 834篇 |
1979年 | 696篇 |
1978年 | 632篇 |
1977年 | 469篇 |
1976年 | 579篇 |
1975年 | 433篇 |
1974年 | 393篇 |
1973年 | 354篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
10.
Qing-Yang Que Lin-Cheng Zhang Jia-Qi Bao Sun-Bin Ling Xiao Xu 《World journal of gastrointestinal surgery》2022,14(5):397-408
Over the last 40 years, the incidence and prevalence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have continued to increase. Compared to other epithelial neoplasms in the same organ, GEP-NENs exhibit indolent biological behavior, resulting in more chances to undergo surgery. However, the role of surgery in high-grade or advanced GEP-NENs is still controversial. Surgery is associated with survival improvement of well-differentiated high-grade GEP-NENs, whereas poorly differentiated GEP-NENs that may benefit from resection require careful selection based on Ki67 and other tissue bio markers. Additionally, surgery also plays an important role in locally advanced and metastatic disease. For locally advanced GEP-NENs, isolated major vascular involvement is no longer an absolute contraindication. In the setting of metastatic GEP-NENs, radical intended surgery is recommended for patients with low-grade and resectable metastases. For unresectable metastatic disease, a variety of surgical approaches, including cytoreduction of liver metastasis, liver transplantation, and surgery after neoadjuvant treatment, show survival benefits. Primary tumor resection in GEP-NENs with unresectable metastatic disease is associated with symptom control, prolonged survival, and improved sensitivity toward systemic therapies. Although there is no established neoadjuvant or adjuvant strategy, increasing attention has been given to this emerging research area. Some studies have reported that neoadjuvant therapy effectively reduces tumor burden, improves the effectiveness of subsequent surgery, and decreases surgical complications. 相似文献